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to Ciproﬂ  oxacin
To the Editor: Reduced suscep-
tibility to ciproﬂ  oxacin  of  Neisseria 
meningitidis has been reported with 
increasing frequency since 1992, 
mainly because of mutations in the 
quinolone resistance determining re-
gions (QRDRs) of the gyrase and 
topoisomerase IV genes (1,2). Re-
duced  ﬂ  uoroquinolone  susceptibility 
due to gyrase A mutations in serogroup 
A strains has previously been reported 
from a 2005 outbreak in Delhi, India 
(1). We describe 2 clinical isolates of 
serogroup A N. meningitidis with re-
duced ciproﬂ  oxacin susceptibility that 
were recognized in March 2003 and 
April 2006 in Israel, a country with 
low incidence of invasive meningo-
coccal disease (<2/100,000/laborato-
ry-conﬁ  rmed cases/year) in which this 
serogroup accounts for <2% of cases 
(data from the National Center for 
Meningococci, Tel Hashomer, Israel). 
The 2 isolates in question 
(M12/03 and M24/06; sufﬁ  xes denote 
year of isolation) were compared with 
2 fully susceptible strains, M44/01 
and M23/00 (online Appendix Table, 
available from www.cdc.gov/EID/
content/14/10/1667-appT.htm). MICs 
were measured by Etest (AB Biodisk, 
Solna, Sweden) on Mueller-Hinton 
agar (Difco Laboratories, Detroit, MI, 
USA) supplemented with 5% sheep 
blood. Demographic information was 
obtained from the Israel Ministry of 
Health Department of Epidemiology. 
Chromosomal DNA was isolated 
by using the NucleoBond kit (Mach-
erey-Nagel, Düren, Germany). The 
location of the QRDR in gyrase and 
topoisomerase IV genes was based 
upon prior studies in meningococci 
(online Appendix Table)  and on the 
complete sequence of  strain N. men-
ingitidis Z2491 (serogroup A; Gen-
Bank accession no. NC_003116). We 
ampliﬁ   ed and sequenced extended 
regions encompassing the QRDRs by 
using the upstream and downstream 
primer pairs in gyrA (522 bases) 5′-
GTTCCGCGTCAAAATATGCT-3′, 
5′-CCGAAATTGACGGTTTCTTC-
3′; gyrB (649 bases) 5′-GGTTTGACC
TGCGTGTTGTC-3′, 5′-CGGCTGG
GCGATATAGATG-3′;  parC  (635 
bases) 5′-CACTATGGTTTGCCGT
TTTG-3′, 5′-ATTTCGGACAACAG
CAATTC-3′; and parE (610 bases) 5′-
GGACAGGATGGCGATTTTG-3′, 5′-
CGTCAGCAACTTCATCAACC-3′. 
PCR was performed by using Taq 
DNA polymerase (New England 
BioLabs, Beverly, MA, USA). DNA 
sequencing was performed using the 
ABI PRISM 3700 Genetic Analyzer 
(Applied Biosystems, Foster City, 
CA, USA). Screening for plasmid-
mediated quinolone resistance genes 
was carried out by multiplex PCR am-
pliﬁ  cation of qnrA, qnrB, and qnrS as 
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previously described (3). Multilocus 
sequence typing (MLST) was carried 
out by using the primers, protocols, 
and databases available from the Neis-
seria MLST website (http://pubmlst.
org/neisseria) (4). 
The online appendix Table shows 
our results and condenses previously 
published ﬁ  ndings. The ciproﬂ  oxacin 
MIC for M24/06 was 42- to 125-fold 
higher than for susceptible strains and 
consistently 2-fold higher than that for 
M12/03. We have not referred to our 
isolates as resistant, because M12/03 
would be categorized as “intermedi-
ate” by Clinical Laboratory Standards 
Institute breakpoints (5). The extended 
QRDRs in gyrA and parC of M44/01 
(susceptible) were identical to those 
of  N. meningitidis Z2491. M24/06 
and M12/03 had a Thr91Ile mutation 
in gyrA. M24/06 also had Asn103Asp, 
Ile111Val, and Val120Ile mutations in 
gyrA (online Appendix Table; 1). In 
M12/03, an Ala78Val mutation was 
found in gyrA, and new mutations 
Ile474Leu and Thr365Ala were found 
in  gyrB and parE, respectively. No 
parC mutations were found. 
Previous reports identiﬁ  ed chro-
mosomal mutations in N. meningitidis 
(online Appendix Table). M24/06 and 
M12/03 possess the same Thr91Ile 
mutation in gyrA as a 2002 serogroup 
B isolate from Spain (online Appendix 
Table)  that had a similar increase in 
ciproﬂ  oxacin MIC (0.12 mg/L). The 
Thr91Ile mutation is homologous with 
the Ser83Leu mutation in gyrA of Es-
cherichia coli that is responsible for a 
60-fold increase in ciproﬂ  oxacin MICs 
(6). Further mutations in a primary tar-
get enzyme (gyrase) have been associ-
ated with additional 2-fold increases 
in the MIC of ciproﬂ  oxacin (7). The 
level of resistance observed in M24/06 
might suggest additional mechanisms. 
An efﬂ  ux pump mechanism is unlike-
ly; we showed no reduction in MICs 
in the presence of reserpine (online 
Appendix Table) and this organism 
was fully susceptible to penicillin, 
tetracycline, erythromycin, and Triton 
X-100 (data not shown). This ﬁ  nd-
ing suggests the absence of  an efﬂ  ux 
pump encoded by a mutated mtrRCDE 
(8). Neither M24/06 nor M12/03 had 
plasmid-mediated genes qnr genes or 
elevated kanamycin MICs, suggest-
ing the presence of aac(6′)-Ib-cr. Both 
of these genes can confer low-level 
quinolone-resistance and facilitate the 
emergence of higher level resistance 
(9) (data not shown). 
MLST showed that M24/06 and 
M12/03 did not derive from a single 
clone after selection of the T91I muta-
tion. M12/03 was sequence type (ST) 
2 and was isolated from a recent im-
migrant from Russia, which is the ori-
gin of most ST 2 strains deposited in 
the Neisseria MLST database (29/34 
records; 85%). M24/06 was ST4789 
in the ST5 clonal complex, isolated 
from a person who had immigrated 
many years previously from Romania. 
ST4789 has been encountered only 
once previously, in Dhaka, Bangla-
desh. 
Disease associated with serogroup 
A N. meningitidis has been extremely 
unusual in Israel (10) and has remained 
rare. This serogroup comprised only 9 
(1.9%) of all 463 isolates submitted 
during 1997–2006 (data from the Na-
tional Center for Meningococci). 
The isolates described in our 
study conﬁ  rm that serogroup A should 
be added to the list of meningococci 
with the potential for reduced ﬂ  uoro-
quinolone susceptibility and raise the 
question why they have appeared in a 
region with particularly low serogroup 
A meningococcal disease incidence 
while frequently encountered sero-
groups have remained fully suscep-
tible. The importance of continuous 
monitoring for reduced ciproﬂ  oxacin 
susceptibility in these more prevalent 
serogroups has been emphasized by 
the recent replacement of rifampin by 
ciproﬂ   oxacin as the preferred agent 
for chemoprophylaxis of meningococ-
cal disease in adults in Israel.  
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Identiﬁ  cation of All 
Dengue Serotypes 
in Nepal 
To the Editor: Nepal is situ-
ated on the southern slopes of the 
Himalayas, surrounded by India on 3 
sides and China to the north. Nepal’s 
altitude ranges from 8,848 m in the 
Himalayas to 90 m in the Terai, the 
southern, low, ﬂ  atland bordering In-
dia. Nepal is a disease-endemic area 
for many vector-borne diseases, in-
cluding malaria, kala-azar, Japanese 
encephalitis, and lymphatic ﬁ  lariasis. 
Because of the porous border between 
Nepal and India, social, cultural, and 
economic activities in cross-border ar-
eas are common. 
Dengue is an emerging disease 
in Nepal; presumably transmission is 
moving north from India into the Terai 
(1–5). The ﬁ  rst report of dengue virus 
isolation or RNA (serotype 2 with nu-
cleotide homology closest to a dengue 
virus type 2 isolate from India) was 
in 2008 involving a  Japanese patient 
returning from Nepal in October 2004 
(5). Entomologic investigations from 
the 1980s showed Aedes albopictus in 
the Terai plains, but Ae. aegypti has 
not been previously reported.
After Indian outbreaks now 
known to include all 4 dengue sero-
types (6), a team from the Epidemi-
ology and Disease Control Division, 
Kathmandu, investigated suspected 
cases of dengue fever during Septem-
ber–October 2006 in Banke, the dis-
trict bordering Uttar Pradesh, India. 
The team collected blood samples 
from persons in Banke and, subse-
quently, from persons in a number 
of other districts and sent them to the 
National Public Health Laboratory in 
Kathmandu or the Armed Forces Re-
search Institute of Medical Sciences, 
Bangkok, Thailand for analysis with 
ELISA, reverse transcription–PCR, 
(RT-PCR), or both. 
Case deﬁ  nitions for dengue fever 
were adopted based on World Health 
Organization guidelines (7). Blood 
samples were obtained from patients 
with an acute febrile illness of 2–7 
days’ duration and with >2 of the 
following manifestations: headache, 
retro-orbital pain, muscular or joint 
pain, and rash. If laboratory tests were 
positive, cases were conﬁ  rmed.  Re-
sults were conﬁ  rmed by ELISA per-
formed at the Armed Forces Research 
Institute of Medical Sciences as pre-
viously described (8). Positive results 
were immunoglobulin (Ig) M >40 
units or IgG >100 units. RT-PCR was 
performed by extracting RNA from 
140 μL of each serum sample using 
QIAGEN Viral RNA Extraction Kit 
per manufacturer’s instructions (QIA-
GEN, Germantown, MD, USA). RT-
PCR and nested PCR were conducted 
according to the Lanciotti protocol 
(9) with the following modiﬁ  cations. 
Reverse transcriptase from avian my-
eloblastosis virus (Promega, Madi-
son, WI, USA) was used in the ﬁ  rst 
round RT-PCR. The concentrations of 
the primers used in the RT-PCR and 
nested reactions were reduced from 50 
pmol to 12.5 pmol per reaction, and 
the number of nested PCR ampliﬁ  ca-
tion cycles was increased to 25.
Serum specimens were obtained 
from 70 suspected case-patients from 
16 districts from October 13 through 
December 3, 2006; 25 conﬁ  rmed cas-
es (13 by ELISA, 10 by RT-PCR, and 
2 by both tests) came from 9 districts 
(Table). The average age was 29 years 
(range 5–65 years); 80% of the case-
patients were men. Three patients had 
a history of travel to India, but clus-
ters of dengue fever cases reported in 
October (Banke and Dang districts) 
indicated local transmission was oc-
curring among patients with no travel 
history. The Terai districts accounted 
for 80% of cases. Entomologic col-
lections done indoors and outside at 
5 different sites reporting suspected 
cases identiﬁ  ed Ae. albopictus and Ae. 
aegypti in all 5 districts. 
These clinical and laboratory test 
results conﬁ  rmed the presence of all 
4 dengue serotypes. Notably, patients 
from the Dang district had no travel 
history outside the Dang valley. Be-
cause Aedes spp. have been identiﬁ  ed 
in Dang, the data strongly suggest 
the existence of an endemic cycle of 
dengue. Underreporting is expected 
in the absence of diagnostic facilities 
at the ﬁ  eld level. It is unclear whether 
the predominance of male patients is 
indicative of greater outdoor as op-
posed to indoor transmission. Of note, 
Ae. albopictus has been found in the 
country since the 1980s; in this study, 
we found Ae. aegypti in Nepal. Men 
typically wear short-sleeved clothes 
due to hot and humid conditions and, 
therefore, are frequently exposed to 
mosquito bites. However, men may 
also access the healthcare system 
more frequently. The ages of case-pa-
tients point to a relative lack of dengue 
immunity among the older population, 
and this ﬁ  nding is consistent with a 
new introduction of dengue. Because 
dengue hemorrhagic fever appears 
when >1 serotype becomes endemic 
to an area (10), the presence of all 4 
serotypes portends the emergence of 
more severe dengue disease in Nepal. 
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